The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- FDA Accepts sNDA for Lenvima’s HCC Indication
September 27, 2017
- Medipal’s JCR Deal Aimed at Adding Value to Its Distribution Biz in Japan?
September 27, 2017
- Konica Minolta to Acquire Boston CRO Invicro
September 26, 2017
- Mitsubishi Tanabe Seeks to Block Talion Generic Launches by 3 Makers
September 26, 2017
- Hisamitsu Launches US PII Study for Analgesic Transdermal Patch
September 26, 2017
- Shionogi Initiates Rolling NDA Submission in US for Lusutrombopag
September 26, 2017
- Daiichi Sankyo’s Esaxerenone Hits Primary Endpoint in Patients with Essential Hypertension
September 26, 2017
- Medipal/JCR Want to Establish JV by Year End, Go Global with 8 Products
September 25, 2017
- Pfizer to Discontinue 5 Generics, Transition Period Slated until March 2019
September 25, 2017
- Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
- Asahi Kasei Obtains Japan Development Rights for Autologous Cell Therapy Product from Belgium Company
September 25, 2017
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda
September 22, 2017
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US
September 22, 2017
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head
September 22, 2017
- CSL Ramping Up Investment for New Product Development, 11% R&D-to-Sales Ratio “Appropriate”: CEO
September 22, 2017
- Japan Oncology Market to Grow Annual 6-9% through 2021: IMS
September 21, 2017
- Opdivo Approved for Non-Squamous NSCLC in Taiwan
September 21, 2017
- Intuniv Hits Primary Endpoint in Adult ADHD: Shionogi/Shire
September 21, 2017
- Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia
September 21, 2017
- hsCRP Levels Will Be Cardiovascular Risk Predictor: Takeda’s Post-Hoc Analysis from EXAMINE Study
September 21, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…